This phase 3 randomized clinical trial compares the efficacy and safety of Janus kinase 2 inhibitor pacritinib with that of best available therapy, including ruxolitinib, in patients with myelofibrosis and thrombocytopenia.
http://ift.tt/2FzEorg
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου